Ne vada Ove r dose Data to Ac tion Sur ve illanc e Compone nt - - PowerPoint PPT Presentation

▶
ne vada ove r dose data to ac tion sur ve illanc e
SMART_READER_LITE
LIVE PREVIEW

Ne vada Ove r dose Data to Ac tion Sur ve illanc e Compone nt - - PowerPoint PPT Presentation

Oct 30, 2023 39 likes •254 views

Ne vada Ove r dose Data to Ac tion Sur ve illanc e Compone nt Re vie w E lyse Mo nro y |Pro g ra m Ma na g e r Sha wn T ho ma s, MPH | Surve illa nc e Co o rdina to r Ne va da Pub lic He a lth T ra ining Ce nte r |UNR, Sc ho o l o

slide-1
SLIDE 1

Ne vada Ove r dose Data to Ac tion Sur ve illanc e Compone nt Re vie w

E lyse Mo nro y |Pro g ra m Ma na g e r Sha wn T ho ma s, MPH | Surve illa nc e Co o rdina to r

Ne va da Pub lic He a lth T ra ining Ce nte r |UNR, Sc ho o l o f Co mmunity He a lth Sc ie nc e

slide-2
SLIDE 2

Pre se nta tion Hig hlig hts

 CDC Ove rdo se Da ta to Ac tio n Pro g ra m Ove rvie w  Ne va da Ove rdo se Da ta to Ac tio n Ove rvie w 

F unding & Go a ls

 Surve illa nc e Co mpo ne nt Stra te g ie s

 Drug Ove rdo se Surve illa nc e E

pide mio lo g y (DOSE )

 Sta te Uninte ntio na l Drug Ove rdo se Re po rting Syste m (SUDORS)

 Ra pid Co unt

 I

nno va tive Surve illa nc e Stra te g ie s

 Ope nBe ds  YRBS

slide-3
SLIDE 3

CDC OD2A

 Building o n Pa st Pro g ra ms

 E

nha nc e d Sta te Opio id Ove rdo se Surve illa nc e

 E

SSE NCE

 SUDORS

 Pre ve ntio n fo r Sta te s

 PDMP

 Crisis Co o pe ra tive Ag re e me nt

 Misc e lla ne o us ‘ One Sho t’ inc lude F

AST / MOST da ta Co lle c tio n a nd AB474 Da ta c o lle c tio n T

  • o ls; a nd

Jurisdic tio na l Vulne ra b ility Asse ssme nt

“T

  • suppo r

t r e c ipie nts in ge tting high quality, c o mple te , and time lie r data o n

  • pio id pr

e sc r ibing and o ve r do se s, and to use tho se data to info r m pr e ve ntio n and r e spo nse ”

  • NCIPC OD2A NOF

O

slide-4
SLIDE 4

OD2A Prog ra m Compone nts

Sur ve illanc e

 Mo rb idity

 DOSE

(E SSE NCE )

 Mo rta lity

 SUDORS (F

  • re nsic T
  • x

 Ra pid OD De a th Co unt

 I

nno va tio n

 Re a l T

ime T re a tme nt Surve illa nc e

 YRBS Co mmunity T

re nd Ana lysis

Pr e ve ntion

 I

nte g ra tio n o f Sta te a nd L

  • c a l E

ffo rts

 L

inka g e s to Ca re & He a lth Syste m Suppo rt

 Pub lic He a lth a nd Pub lic Sa fe ty

Co o rdina to r

 E

mpo we r Pe o ple to Ma ke Sa fe r Cho ic e s

slide-5
SLIDE 5

Ne vada’s OD2A Pr

  • gr

am

Proje c t Pe riod: Se pte mbe r 1, 2019 – Aug ust 31, 2022

Ye a r 1 Budg e t Pe riod- Se pt 1,2019- Aug ust 31, 2020

T

  • ta l Ye a r 1: $4,228,798.00

Pr

  • je c t Par

tne r s (Sub- r e c ipie nts)

 Bo a rd o f Pha rma c y  Wa sho e Co unty He a lth Distric t  Wa sho e Co unty Co ro ne r Me dic a l E

xa mine r

 So uthe rn Ne va da He a lth Distric t  Cla rk Co unty Co ro ne r  UNR CHS  NyECo mmunity Co a litio n  Pa rtne rship Ca rso n City  PACT

Co a litio n

 PACE

Co a litio n

 Jo in T

  • g e the r No rthe rn Ne va da

 SE

I

slide-6
SLIDE 6

Ne va da OD2A Prog ra m Goa ls

Decision Making

  • Improved decision making, resource allocation, and informed intervention strategies, based on improved quality and

dissemination of fatal and non-fatal substance abuse and opioid use data

Prescribers Tools

  • Enhanced Prescription Drug Monitoring Program (PDMP) that supports evidence-based prescribing, and data sharing to

inform prevention and intervention strategies

Linkage to Care

  • Increase the number of individuals referred for substance use/ opioid use/ supportive services from a clinical or

community-based setting through health systems, and community- based providers, by streamlining the referral process

Local Capacity

  • Communities have increased capacity to respond to Opioid and Substance Use Disorder and are better equipped to

respond to crisis, and support individuals through recovery

Increased Awareness

  • Increased awareness about opioid use, poly drug risk, and increased awareness about OUD stigma, treatment, and

recovery

“Ac tive Surve illa nc e ” I nte g ra tio n & Na rxCa re Ope nBe ds Sub sta nc e a b use spe c ia lists, PH/ PS Co o rdina tio n E B Pre ve ntio n Pro g ra mming & Pub lic Me ssa g ing

slide-7
SLIDE 7

Sur ve illanc e Str ate gy 1

DOSE Da ta Re po rting a nd Disse mina tio n

slide-8
SLIDE 8

DOSE Re porting

 Ob je c tive : Co lle c t a nd disse mina te time ly e me rg e nc y de pa rtme nt (E

D) da ta o n suspe c te d a ll drug , a ll o pio id, he ro in, a nd a ll stimula nt o ve rdo se s.

 Sub sta nc e use re la te d e me rg e nc y de pa rtme nt visits fro m Na tio na l Syndro mic Surve illa nc e

Pro g ra m.

 Suspe c te d a ll-drug , o pio id, he ro in, a nd stimula nt-re la te d visits

 De fine d b y c a se de finitio ns pro vide d b y CDC utilizing c hie f c o mpla int ke ywo rds a nd I

CD-10-CM disc ha rg e dia g no sis c o de s.

 Re po rte d to CDC b i-we e kly a nd mo nthly.

slide-9
SLIDE 9

F ig ure 1. T he re wa s a sig nific a nt de c r e asing tre nd in a ll- drug , opioid, he roin, a nd stimula nt E D visits from July 2019 to De c e mbe r 2019 (ra te s pe r 10,000 E D visits)

All Drug, 69.8 59.4 Opioid, 20.4 16.2 Heroin, 4.4

3.7

Stimulant, 6.2 5.4

July 2019 Aug 2019 Sept 2019 Oct 2019 Nov 2019 Dec 2019

slide-10
SLIDE 10

F igur e 2. T he r e was a signific ant de c r e asing tr e nd in all- dr ug E D visits in fe male s fr

  • m July 2019 to De c e mbe r

2019 (r ate s pe r 10,000 E D visits)

All Drug , 63.5 51.8 Opioid, 14.2 13.4

July 2019 Aug 2019 Sept 2019 Oct 2019 Nov 2019 Dec 2019

slide-11
SLIDE 11

F igur e 3. T he r e was a signific ant de c r e asing tr e nd in all- dr ug, opioid, he r

  • in, and stimulant E

D visits in male s fr

  • m

July 2019 to De c e mbe r 2019 (r ate s pe r 10,000 E D visits)

All Drug, 77.2 68.4 Opioid, 27.6 19.5 Heroin, 7.9 5.4 Stimulant, 10.5 7.8

July 2019 Aug 2019 Sept 2019 Oct 2019 Nov 2019 Dec 2019

slide-12
SLIDE 12

F igur e 4. T he r e was a signific ant de c r e asing tr e nd in all- dr ug E D visits in the 0- 14 and 55+ age gr

  • ups fr
  • m July 2019

to De c e mbe r 2019 (r ate s pe r 10,000 E D visits)

0-14 years, 42.5 35.2 15-24 years, 101.0 98.7 25-34 years, 84.2 77.5 35-54 years, 78.5 69.1 55+ years, 54.1 41.3

July 2019 Aug 2019 Sept 2019 Oct 2019 Nov 2019 Dec 2019

slide-13
SLIDE 13

Sur ve illanc e Str ate gy 2

SUDORS Da ta Re po rting a nd Disse mina tio n

slide-14
SLIDE 14

SUDORS Re porting

 Ob je c tive : Co lle c t a nd disse mina te de sc riptio ns o f drug o ve rdo se de a th c irc umsta nc e s

using de a th c e rtific a te s a nd ME / C da ta

 Ab stra c to rs fro m Wa sho e Co unty C/ ME

a nd So uthe rn Ne va da He a lth Distric t re vie w de a ths fo r the c o untie s in the ir jurisdic tio ns a nd a b stra c t the m into NVDRS.

 Ca pture s de ta ile d info o n to xic o lo g y, de a th sc e ne inve stig a tio ns, ro ute o f a dministra tio n,

a nd o the r risk fa c to rs tha t ma y b e a sso c ia te d with a fa ta l o ve rdo se .

 Re po rte d to CDC e ve ry 6 mo nths

slide-15
SLIDE 15

SUDORS Ra pid Opioid Ove rdose De te c tion

 Ob je c tive : T

  • mo re ra pidly de te c t o pio id o ve rdo se o utb re a ks o r sha rp inc re a se s in o pio id
  • ve rdo se de a ths.

 Co lla b o ra ting with the Cla rk Co unty Offic e o f the Co ro ne r/ Me dic a l E

xa mine r to c o lle c t pre limina ry da ta o n suspe c te d o pio id o ve rdo se s

 Da ta c o lle c tio n b e g ins Ma y 1, 2020.

slide-16
SLIDE 16

Sur ve illanc e Str ate gy 3

I nno va tive Surve illa nc e I nitia tive s

slide-17
SLIDE 17

YRBS T re nd Ana lysis

 Wo rking to g e the r with UNR to do 3-ye ar tre nd analysis o f sub stanc e use indic ato rs (2015-2019).  Will o ve rlay the se tre nds with o pio id mo rb idity and mo rtality tre nds.  E

me rg e nc y de partme nt visits

 Mo rtality data (SUDORS)  PDMP  With o the r Ne vada datase ts  Ne vada Re po rt Card  Juve nile Justic e  Altho ug h c anno t draw dire c t c o mpariso ns b e twe e n the tre nds in YRBS and o the r data so urc e s, this

pro je c t aims to sho w the tre nds o f ado le sc e nt risk fac to rs and o pio id mo rb idity and mo rtality data

  • ve r time .
slide-18
SLIDE 18

T re a tme nt Ava ila bility Surve illa nc e - T hroug h Ope nBe ds

 Ope nBe ds e le c tro nic b e havio ral he alth re fe rral syste m

 Ac ute Care Ho spitals  I

n Patie nt Psyc

 SAPT

A F unde d T re atme nt Pro vide rs

 Rural Clinic s

 Mo nito ring o f state wide inpatie nt and o utpatie nt tre atme nt availab ility.  Sub stanc e  ASAM L

e ve o f Care Ne e de d

 Paye rs

slide-19
SLIDE 19
slide-20
SLIDE 20

T re a tme nt Ava ila bility Surve illa nc e - T hroug h Ope nBe ds

 Ne two rk L

aunc h thre sho ld: 70%

 T

arg e t T ime F rame : L ate May

slide-21
SLIDE 21

Que stions? E lyse Mo nro y| Pro g ra m Ma na g e r e c mo nro y@ unr.e d u 775-229-5783 Sha wn T ho ma s | Surve illa nc e Co o rdina to r Sha wnT @ me d .unr.e d u 775-470-0496